卵巢癌生物治疗新进展

doi:10.3760/cma.j.issn.1673-422X.2013.11.018

摘要/Abstract

摘要： 近年卵巢癌的生物治疗有了很大进展,包括肿瘤疫苗和过继免疫细胞治疗在内的免疫治疗可提高机体的免疫识别能力，而针对肿瘤细胞生长过程中不同靶点的单抗和酪氨酸激酶抑制剂等分子靶向药物的应用也取得了很大的临床获益，激素替代治疗、中医治疗等也在一定程度上改善了卵巢癌患者的生活质量。

关键词: 卵巢肿瘤, 免疫疗法, 分子靶向治疗

Abstract: In recent years, the biological therapy of ovarian cancer has made great progress. Immunotherapy including tumor vaccine and adoptive immunity cell therapy can improve immune recognition capability, while the applications of molecular targeted drugs such as monoclonal antibodies and tyrosine kinase inhibitors for different target spots during the tumor cells growth progresses achieve significant clinical benefit, as well as hormone replacement therapy and Chinese medicine treatment improve the life quality of patients with ovarian cancer to a certain degree.

Key words: Ovarian neoplasms, Immunotherapy, Molecular targeted therapy

许辉茹, 冯慧晶, 张俊萍. 卵巢癌生物治疗新进展[J]. 国际肿瘤学杂志, 2013, 40(11): 861-864.

XU Hui-Ru, FENG Hui-Jing, ZHANG Jun-Ping. Biological therapy of ovarian cancer[J]. Journal of International Oncology, 2013, 40(11): 861-864.

参考文献

［1］ Tanyi JL, Chu CS. Dendritic cellbased tumor vaccinations in epithelial ovarian cancer: a systematic review. Immunotherapy, 2012, 4(10): 995-1009. ［2］程志勇. DC-CIK在卵巢癌治疗中的疗效观察. 中国医药指南, 2012, 10 (14):149-150. ［3］桑圣刚, 荣红. DC-CIK细胞治疗对晚期卵巢癌患者外周血CK19-mRNA表达的影响. 海南医学院学报, 2012,18(5):610-613. ［4］Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med, 2011, 365(26):2484-2496. ［5］Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med, 2011, 365(26):2473-2483. ［6］Garcia AA, Hirte H, Fleming G, et al. Phase Ⅱ clinical trial of bevacizumab and lowdose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California，Chicago，and Princess Margaret Hospital phaseⅡ consortia．J Clin Oncol, 2008, 26(1):76-82. ［7］Heitz F, Harter P, Barinoff J, et al． Bevacizumab in the treatment of ovarian cancer. Adv Ther， 2012,29(9):723-735. ［8］Siwak DR, Carey M, Hennessy BT, et al. Targeting the epidermal growth facter receptor in epithelial ovrian cancer: current knowledge and future chanllenges. J Oncol, 2009, 69(1):1-20. ［9］Secord AA, Blessing JA, Armstrong DK, et al. Phase Ⅱ trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol, 2008, 108(3):493-499．［10］Schilder RJ, Pathak HB, Lokshin AE, et al. Phase Ⅱ trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol, 2009, 113(1):21-27. ［11］Pautier P, Joly F, Kerbrat P, et al. Phase Ⅱ study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma(1839IL/0074). Gynecol Oncol, 2010, 116(2):157-162. ［12］Vasey PA, Gore M, Wilson R, et al. A phase Ⅰb trial of docetaxel，carboplatin and erlotinib in ovarian，fallopian tube and primary peritoneal cancers．Br J Cancer, 2008, 98(11):1774-1780. ［13］Kimball KJ, Numnum TM, Kirby TO, et al. A phase Ⅰ study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma. Gynecol Oncol, 2008, 111(1):95-101. ［14］Weroha SJ, Oberg AL, Ziegler KL, et al. Phase Ⅱ trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol, 2011,122(1): 116-120. ［15］Armstrong DK, White AJ, Weil SC, et al. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovariancancer. Gynecol Oncol, 2013, 129(3):452-458. ［16］Bodnar L, Gornas M, Szczylik C. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer：a phase Ⅱ study. Gynecol Oncol, 2011, 123（1）：33-36. ［17］WilkinsonRyan I, Mutch D. A review of iniparib in ovarian cancer. Expert Opin Investig Drugs, 2013, 22(3):399-405. ［18］Reyners AK, de Munck L, Erdkamp FL, et al. A randomized phase Ⅱ study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage ⅠC to Ⅳ epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study. Ann Oncol, 2012, 23(11):2896-2902. ［19］ Murdoch WJ, Van Kirk EA, Isaak DD, et al. Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts．Gynecol Oncol, 2008, 110(2):251-255．［20］Psyrri A, Kountourakis P, Yu Z, et al. Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets. Ann Oncol, 2007, 18(4):709-715．

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[4]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[5]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[6]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[7]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[8]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[9]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[10]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[11]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[12]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[13]	马正红, 姜超. 非小细胞肺癌KRAS^G12C突变的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 95-98.
[14]	崔腾璐, 吕璐, 孙鹏飞. 放疗联合免疫治疗在头颈部鳞状细胞癌治疗中的应用[J]. 国际肿瘤学杂志, 2023, 50(9): 548-552.
[15]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.